Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 239

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 239
---
| Annual variable compensation              |        N/A |         N/A |        N/A |         N/A |
| Exceptional compensation                  |        N/A |         N/A |        N/A |         N/A |
| Compensation for serving as a director(b) |        N/A |         N/A |        N/A |         N/A |
| Benefits in kind                          |      4,836 |       4,836 |      2,418 |       2,418 |
| Total                                     |    884,836 |     884,836 |    528,505 |     528,505 |

The amounts reported are gross amounts before taxes. (a) Fixed compensation due in respect of a given year is paid during that year. (b) Compensation awarded to Frédéric Oudéa for service as a non-voting Board member, an office he held from September 2, 2022 to May 25, 2023 (the date on which he was appointed Chairman of the Board of Directors), is disclosed in the section entitled "Compensation elements and benefits of all kinds paid during 2024 or awarded in respect of 2024 to directors" above. Compensation and benefits of all kinds paid during 2024 or awarded in respect of 2024 to Paul Hudson, Chief Executive Officer Paul Hudson has served as Chief Executive Officer of Sanofi since September 1, 2019, and holds office for an indeterminate period. Paul Hudson does not have a contract of employment with Sanofi, and receives no compensation from any company included in Sanofi’s scope of consolidation within the meaning of Article L. 233-16 of the French Commercial Code. Compensation awarded to Paul Hudson (table No. 1 of the AFEP-MEDEF Code)

| (€)                                                                         |      2024 |       2023 |
| Compensation awarded for the year (details provided in the following table) | 3,979,697 |  3,792,797 |
| Valuation of performance shares awarded during the year(a)                  | 5,971,350 |  6,779,025 |
| Total                                                                       | 9,951,047 | 10,571,822 |

(a) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period. The parameters used to calculate the valuations are market parameters